The FDA on May 29, 2020 approved CYRAMZA® in combination with TARCEVA® (Erlotinib) for first-line treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. CYRAMZA® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
